Different medical institutions have selected different imported and domestic brand instruments: 38 domestic and 58 imported.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

On March 23, 2020, Eli Lilly and Company provided an update on the companys clinical trial activities in light of the COVID-19 pandemic. The company will delay most new study starts and pause enrollment in most ongoing studies. Lilly is con

NEW YORK BioMrieux said on Tuesday that an assay developed by its subsidiary BioFire Defense to rapidly detect COVID-19, the disease caused by SARS-CoV-2 virus, was granted Emergency Use Authorization by the US Food and Drug Administration.

NEW YORK The Japanese Ministry of Health, Labor, and Welfare has approved the MET Inhibitor tepotinib (Merck KGaAs Tepmetko) for non-small cell lung cancer patients with MET exon 15 skipping alterations, after the drug demonstrated meaningf

NEW YORK The US Food and Drug Administration on Friday warned consumers to watch out for companies marketing unproven products for diagnosing, preventing, or treating COVID-19. We will continue to aggressively pursue those who place the pub

NEW YORK While many in the US and Europe have only recently come to understand the scope and severity of the SARS-CoV-2 pandemic, a handful of proteomics labs have been studying the virus since the beginning of the year. These studies have

NEW YORK A new UK-based research consortium is betting that sequencing the virus that causes COVID-19 can provide policymakers with a clearer picture of the spread of the epidemic across the country as diagnostic testing remains limited. I

NEW YORK In a new study published in Nature on Wednesday, researchers in China described the cell type composition of all major human organs, based on the RNA sequences of more than 500,000 single cells from Chinese Han donors. Using single

NEW YORK Personalis reported after the close of the market on Wednesday that its fourth quarter revenues rose 38 percent year over year, driven by an increase in testing volume and analytical services provided to the US Department of Vetera

NEW YORK Oncocyte said after the close of the market on Wednesday that its fourth quarter net loss rose 77 percent year over year as it pushed toward a transition to commercial test operations. For the three-month period ended Dec. 31, 2019

NEW YORK Biocept said after the close of the market on Wednesday that its fourth quarter revenues more than doubled year over year, driven by 46 percent growth in commercial test volume and 34 percent growth in average insurance reimburseme